|
|
Article: Novartis Launches Z-FAST: A Study Evaluating Femara(R) and Zometa(R) in Postmenopausal Women with Early Breast Cancer.
- Article from:
- PR Newswire
- Article date:
- December 10, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
* Study of 500 women combines Femara, a leading aromatase inhibitor, with Zometa, the most widely used IV bisphosphonate * Z-FAST will evaluate adjuvant cancer treatment-related bone loss in postmenopausal women with early breast cancer
Novartis announced today that it is combining two widely used drugs in a trial to evaluate bone loss associated with cancer treatment in postmenopausal women with early breast cancer. The Novartis drugs being paired are Femara(R) (letrozole tablets), a leading aromatase inhibitor in advanced breast cancer, and Zometa(R) (zoledronic acid for injection), the most widely used IV bisphosphonate in treating bone complications of ...